TNG456

TNG456 is a small-molecule drug developed by Tango Therapeutics. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: A selective PRMT5 inhibitor being developed for cancers with MTAP loss/deletion, including glioblastoma. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and glioma & glioblastoma. The largest, NCT06810544, plans to enrol 191 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.